Refine
Year of publication
Document Type
- Article (41)
- Contribution to a Periodical (5)
- Preprint (5)
- Book (2)
- Part of a Book (2)
- Conference Proceeding (2)
Has Fulltext
- yes (57)
Is part of the Bibliography
- no (57)
Keywords
- invasion (4)
- COVID-19 surveillance (2)
- Gastfreundschaft (2)
- Gastfreundschaft, Begriff (2)
- Genetics (2)
- MCAK (2)
- Omicron (2)
- RITA (2)
- SARS-CoV-2 (2)
- SARS-CoV-2 monitoring (2)
Institute
Bipolar disorder (BD) is a leading contributor to the global burden of disease1. Despite high heritability (60-80%), the majority of the underlying genetic determinants remain unknown2. We analysed data from participants of European, East Asian, African American and Latino ancestries (n=158,036 BD cases, 2.8 million controls), combining Clinical, Community, and Self-reported samples. We identified 298 genome-wide significant loci in the multi-ancestry meta-analysis, a 4-fold increase over previous findings3, and identified a novel ancestry-specific association in the East Asian cohort. Integrating results from fine-mapping and other variant-to-gene mapping approaches identified 36 credible genes in the aetiology of BD. Genes prioritised through fine-mapping were enriched for ultra-rare damaging missense and protein-truncating variations in BD cases4, highlighting convergence of common and rare variant signals. We report differences in genetic architecture of BD depending on the source of patient ascertainment and on BD-subtype (BDI and BDII). Several analyses implicate specific cell types in BD pathophysiology, including GABAergic interneurons and medium spiny neurons. Together, these analyses provide novel insights into the genetic architecture and biological underpinnings of BD.
Hintergrund: In der allgemeinmedizinischen Forschung in Deutschland haben sich in den letzten Jahren zunehmend partizipative Forschungsansätze etabliert. Bei dieser Art der Forschung werden die Sichtweisen und das Erfahrungswissen relevanter Interessensgruppen, sogenannte Stakeholder, die bisher oftmals nur Forschungsobjekt waren, aktiv in den Forschungsprozess eingebunden. Im Bereich der Allgemeinmedizin sind neben hausärztlichen Praxisteams (Hausärzt:innen, Medizinische Fachangestellte, weitere Professionen) insbesondere Patient:innen sowie Bürger:innen relevante Stakeholder, durch deren aktive Beteiligung die Relevanz und Machbarkeit von Forschungsprojekten gesteigert werden kann.
Zielsetzung: Mit dieser erfahrungsbasierten Handreichung sollen Wissenschaftler:innen zur aktiven Beteiligung von Stakeholdern an Forschung ermutigt und der Einsatz partizipativer Forschungsansätze weiter gefördert werden. Dabei legt diese Handreichung den Fokus bewusst auf die Besonderheiten allgemeinmedizinischer Forschung und der in diesem Kontext relevanten Stakeholder. Die Handreichung soll Hilfestellungen geben, wie ein Einstieg gelingen kann und was es bei der Planung und Umsetzung von Beteiligungsaktivitäten mit Patient:innen, Bürger:innen, Hausärzt:innen und Medizinischen Fachangestellten zu berücksichtigen gilt.
Methode: Die Eckpunkte für diese Handreichung wurden im Rahmen eines Forschungssymposiums der Initiative Deutscher Forschungspraxennetze DESAM-ForNet erarbeitet, das im April 2024 in Frankfurt am Main stattfand. Bei dem Forschungssymposium kamen 35 Wissenschaftler:innen, Studienassistent:innen und weitere interessierte Mitarbeitende aus allgemeinmedizinischen Forschungspraxennetzen und anderen Institutionen zusammen, um sich zu der Frage „Wie gelingt aktive Forschungsbeteiligung von Patient:innen, Bürger:innen, Hausärzt:innen und Medizinischen Fachangestellten an der allgemeinmedizinische Forschung?“ auszutauschen. Hierfür diskutierten die Teilnehmenden in zwei World Cafés zu den Themen (1) Partizipation planen und umsetzen sowie (2) Besonderheiten der Stakeholder. Die erarbeiteten Inhalte wurden jeweils auf Moderationskarten gesammelt und thematisch geclustert. Auf Grundlage dieser Erfahrungssammlung arbeiteten die Teilnehmenden des Symposiums im Nachgang in kleinen Autor:innengruppen die einzelnen Kapitel der Handreichung aus. Im Sinne der Beteiligung wurde die Handreichung vor Finalisierung durch zwei Patient:innen, zwei Hausärzt:innen und zwei Medizinische Fachangestellte geprüft und kommentiert.
Ergebnisse: Mit Fokus auf der allgemeinmedizinischen Forschung gibt die Handreichung einen umfassenden Überblick über die Zielsetzungen und Gründe aktiver Forschungsbeteiligung, mögliche Methoden, Aspekte der Planung und Organisation von Beteiligungsaktivitäten sowie Ansätze und Instrumente für deren Evaluation. Darüber hinaus beleuchtet sie Besonderheiten der drei zentralen Stakeholdergruppen Patient:innen/Bürger:innen, Hausärzt:innen und Medizinischen Fachangestellte im Hinblick auf Diversität, geeignete Beteiligungsformate, zielgruppengerechte Ansprache, Erwartungsmanagement sowie passende Anreize für die Beteiligung. Da die Inhalte überwiegend erfahrungsbasiert und dadurch limitierend bezüglich der Übertragbarkeit auf andere Kontexte sind, wir die Handreichung durch eine Sammlung an Verweisen auf weitere hilfreicher Ressourcen wie Handbücher, Glossare und Checklisten ergänzt.
Schlussfolgerung: Diese Handreichung zur aktiven Beteiligung von Stakeholdern an allgemeinmedizinischer Forschung spiegelt die Erfahrungen der Autor:innengruppe wider. Sie soll auf diese Weise möglichst anwendungsorientierte und passgenaue Anregungen für den Kontext Allgemeinmedizin geben und noch mehr Kolleg:innen ermutigen, Stakeholder aktiv an Forschung zu beteiligen.
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.
Introduction: Hip fracture surgery is associated with high in-hospital and 30-day mortality rates and serious adverse patient outcomes. Evidence from randomised controlled trials regarding effectiveness of spinal versus general anaesthesia on patient-centred outcomes after hip fracture surgery is sparse.
Methods and analysis: The iHOPE study is a pragmatic national, multicentre, randomised controlled, open-label clinical trial with a two-arm parallel group design. In total, 1032 patients with hip fracture (>65 years) will be randomised in an intended 1:1 allocation ratio to receive spinal anaesthesia (n=516) or general anaesthesia (n=516). Outcome assessment will occur in a blinded manner after hospital discharge and inhospital. The primary endpoint will be assessed by telephone interview and comprises the time to the first occurring event of the binary composite outcome of all-cause mortality or new-onset serious cardiac and pulmonary complications within 30 postoperative days. In-hospital secondary endpoints, assessed via in-person interviews and medical record review, include mortality, perioperative adverse events, delirium, satisfaction, walking independently, length of hospital stay and discharge destination. Telephone interviews will be performed for long-term endpoints (all-cause mortality, independence in walking, chronic pain, ability to return home cognitive function and overall health and disability) at postoperative day 30±3, 180±45 and 365±60.
Ethics and dissemination: iHOPE has been approved by the leading Ethics Committee of the Medical Faculty of the RWTH Aachen University on 14 March 2018 (EK 022/18). Approval from all other involved local Ethical Committees was subsequently requested and obtained. Study started in April 2018 with a total recruitment period of 24 months. iHOPE will be disseminated via presentations at national and international scientific meetings or conferences and publication in peer-reviewed international scientific journals.
Trial registration number: DRKS00013644; Pre-results
The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social factors have a role in the chance of exposure to SARS-CoV-2 and the severity of COVID-191,2, host genetics may also be important. Identifying host-specific genetic factors may reveal biological mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk factors for SARS-CoV-2 infection and outcomes. We formed a global network of researchers to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity. Here we describe the results of three genome-wide association meta-analyses that consist of up to 49,562 patients with COVID-19 from 46 studies across 19 countries. We report 13 genome-wide significant loci that are associated with SARS-CoV-2 infection or severe manifestations of COVID-19. Several of these loci correspond to previously documented associations to lung or autoimmune and inflammatory diseases3,4,5,6,7. They also represent potentially actionable mechanisms in response to infection. Mendelian randomization analyses support a causal role for smoking and body-mass index for severe COVID-19 although not for type II diabetes. The identification of novel host genetic factors associated with COVID-19 was made possible by the community of human genetics researchers coming together to prioritize the sharing of data, results, resources and analytical frameworks. This working model of international collaboration underscores what is possible for future genetic discoveries in emerging pandemics, or indeed for any complex human disease.
Measuring NADPH oxidase (Nox)-derived reactive oxygen species (ROS) in living tissues and cells is a constant challenge. All probes available display limitations regarding sensitivity, specificity or demand highly specialized detection techniques. In search for a presumably easy, versatile, sensitive and specific technique, numerous studies have used NADPH-stimulated assays in membrane fractions which have been suggested to reflect Nox activity. However, we previously found an unaltered activity with these assays in triple Nox knockout mouse (Nox1-Nox2-Nox4-/-) tissue and cells compared to wild type. Moreover, the high ROS production of intact cells overexpressing Nox enzymes could not be recapitulated in NADPH-stimulated membrane assays. Thus, the signal obtained in these assays has to derive from a source other than NADPH oxidases. Using a combination of native protein electrophoresis, NADPH-stimulated assays and mass spectrometry, mitochondrial proteins and cytochrome P450 were identified as possible source of the assay signal. Cells lacking functional mitochondrial complexes, however, displayed a normal activity in NADPH-stimulated membrane assays suggesting that mitochondrial oxidoreductases are unlikely sources of the signal. Microsomes overexpressing P450 reductase, cytochromes b5 and P450 generated a NADPH-dependent signal in assays utilizing lucigenin, L-012 and dihydroethidium (DHE). Knockout of the cytochrome P450 reductase by CRISPR/Cas9 technology (POR-/-) in HEK293 cells overexpressing Nox4 or Nox5 did not interfere with ROS production in intact cells. However, POR-/- abolished the signal in NADPH-stimulated assays using membrane fractions from the very same cells. Moreover, membranes of rat smooth muscle cells treated with angiotensin II showed an increased NADPH-dependent signal with lucigenin which was abolished by the knockout of POR but not by knockout of p22phox. In conclusion: the cytochrome P450 system accounts for the majority of the signal of Nox activity chemiluminescence based assays.
Background: The human ATP-binding cassette, subfamily B, member 11 (ABCB11) gene encodes the bile salt export pump, which is exclusively expressed at the canalicular membrane of hepatocytes. A frequent variant in the coding region, c.1331 T > C, leading to the amino acid exchange p.V444A, has been associated with altered serum bile salt levels in healthy individuals and predisposes homozygous carriers of the [C] allele for obstetric cholestasis. Recently, elevated bile salt levels were shown to be significantly associated with rates and risk of cirrhosis in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon-alpha2 and ribavirin, suggesting a potential role for bile salt levels in HCV treatment outcomes and in the fibrogenic evolution of HCV-related liver disease. The aim of this study was to investigate a possible association of ABCB11 c.1331 T > C with hepatitis C virus (HCV) infection and fibrosis stages as assessed by non-invasive transient elastography in a German cohort of patients.
Methods: ABCB11 c.1331 T > C genotype was determined by allelic discrimination assay in 649 HCV infected cases and 413 controls. Overall, 444 cases were staged for fibrotic progression by measurement of liver stiffness.
Results: Homo- or heterozygous presence of the frequent [C] allele was associated with HCV positivity (OR = 1.41, CI = 1.02 - 1.95, p = 0.037). No association was detectable between the ABCB11 c.1331 T > C genotype and increased liver stiffness.
Conclusions: Our data confirm that homozygous presence of the major [C] allele of ABCB11 c.1331 T > C is a genetic susceptibility factor for HCV infection, but not for liver fibrosis.
Latent transforming growth factor beta binding protein 4 (LTBP4) belongs to the fibrillin/LTBP family of proteins and plays an important role as a structural component of extracellular matrix (ECM) and local regulator of TGFβ signaling. We have previously reported that Ltbp4S knock out mice (Ltbp4S −/−) develop centrilobular emphysema reminiscent of late stage COPD, which could be partially rescued by inactivating the antioxidant protein Sestrin 2 (Sesn2). More recent studies showed that Sesn2 knock out mice upregulate Pdgfrβ-controlled alveolar maintenance programs that protect against cigarette smoke induced pulmonary emphysema. Based on this, we hypothesized that the emphysema of Ltbp4S −/− mice is primarily caused by defective Pdgfrβ signaling. Here we show that LTBP4 induces Pdgfrβ signaling by inhibiting the antioxidant Nrf2/Keap1 pathway in a TGFβ-dependent manner. Overall, our data identified Ltbp4 as a major player in lung remodeling and injury repair.
